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Abstract
Background: To evaluate the efficacy and safety of aspirin usage for coronary heart disease (CHD) primary
prevention in patients with dyslipidemia.
Methods: A cross-sectional study was conducted to enrolled subjects with documented dyslipidemia. A total of
202 patients with dyslipidemia were recruited and 138 were undergone aspirin treatment before this indexed
admission and 64 had never been treated with aspirin. All subjects were undergone coronary angiography to
diagnoses CHD. Clinical characteristics were collected and comparisons were performed between subjects with
aspirin and subjects without aspirin therapy. Logistic regression analysis was conducted to assess the relation
between aspirin and incident CHD and bleeding events.
Results: Compared to those with aspirin therapy, CHD incidence was significantly higher in subjects without aspirin
therapy (23.4 % versus 18.1 %, P < 0.05). Five patients in the aspirin group had gastrointestinal bleeding and no
bleeding event was occurred in subjects without aspirin therapy. Subjects with aspirin therapy had higher rate of
previous helicobacter pylori (HP) infection (8.7 % versus 4.7 %, P < 0.05). Compared to subjects without CHD, subjects
with CHD were older, had higher frequencies of males and smokers, had higher heart rate, serum LDL cholesterol,
Lp(a) and Hs-CRP levels. Percentages of subjects with hypertension, diabetes, gastrointestinal bleeding, and HP
infection were also considerably higher in CHD group (P < 0.05 for all comparison). Logistic regression analysis
revealed that aspirin was associated with reduced incidence of CHD, with odds ratio (OR) of 0.85 (95 % confidence
interval (CI): 0.80-0.94, P < 0.05). Regarding safety endpoint, gastrointestinal bleeding risk associated with aspirin was
attenuated to nonsignificant after adjusting for HP infection, with OR of 1.16 (95 % CI: 0.99-1.52, P = 0.178).
Conclusion: Aspirin is beneficial for reducing incident CHD, while modestly increases gastrointestinal bleeding risk.
Screening subjects with previous HP infection may avoid aspirin-related gastrointestinal bleeding.
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Background
The effects of aspirin on secondary prevention of athero-
sclerotic cardiovascular diseases (ASCVD) have been
consistently demonstrated by previous clinical studies [1,
2]. Nonetheless, the efficacies of aspirin on ASCVD pri-
mary prevention are conflicting [3–7]. In addition, as-
pirin may increase bleeding risks such as incident
intracranial hemorrhage and gastrointestinal bleeding [1,
8]. Therefore, it is clinically relevant and important to
balance the risk and benefit of aspirin prescription for
ASCVD primary prevention.
Dyslipidemia is a major risk factor of ASCVD [9], and
increased serum level of low density lipoprotein (LDL)
cholesterol is associated with higher incidence and
prevalence of coronary heart disease (CHD) and ische-
mic stroke [10, 11]. Statins has been broadly used for
lowering serum LDL cholesterol level, which in turn re-
duces cardiovascular events [10, 12, 13]. Nonetheless,
whether aspirin could decrease cardiovascular risk in
subjects with dyslipidemia is uncertain, and the data on
the efficacy of low-dose, enteric-coated and once-daily
aspirin on ASCVD primary prevention in Chinese popu-
lation is also limited. Thus this, we conducted a cross-
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sectional research to explore whether aspirin could re-
duce the incidence of CHD in subjects with documented
dyslipidemia. Moreover, bleeding events presumably
associated with aspirin use would also be evaluated. We
hoped that data from present study would shed lights
for future randomized controlled trials in investigating
whether aspirin prescription could confer beneficial




Studied subjects were consecutively enrolled with a
cross-sectional design from in-patient department and
all subjects were diagnosed with dyslipidemia based on
either serum lipid profiles measurement, self-report or
statins treatment. Informed consent was obtained and
present study was approved by participating hospital
ethnic committee (GRH20150814). Study inclusion cri-
teria were as follow: all enrolled subjects had not been
diagnosed with CHD previously and were undergone
coronary angiography in present indexed admission. Ex-
clusion criteria were those currently treating with anti-
coagulatory agents (e.g. warfarin) or other anti-platelet
drugs (e.g. clopidogrel) were excluded. In brief, diameter
of coronary artery which is equal to or more than 70 %
stenosis of adjacent proximal segment is diagnosed with
CHD as reviewed by two independent investigators.
Studied subjects were divided into two groups in
terms of with and without CHD and between-group
differences were conducted. In addition, studied sub-
jects were also divided into with and without aspirin
therapy groups and between-group differences were
also performed.
Clinical characteristics collection
Demographic data including gender, age, and smoking
status were extracted from in-patient medical document.
Anthropometric parameters collections including sys-
tolic/diastolic blood pressure (SBP/DBP) at sitting, heart
rate (HR) at rest, waist and hip circumferences using for
calculating waist-hip ratio were performed by two expe-
rienced investigators. Laboratory examination results in-
cluding total cholesterol (TC), triglyceride (TG), high
density lipoprotein (HDL) cholesterol, LDL cholesterol,
lipoprotein(a) (Lp(a)), apolipoprotein A1 (apoA1), apoli-
poprotein B (apoB), fasting plasma glucose (FPG) and
glycated hemoglobin (HbA1c) were measured by using
electrochemical method and high sensitivity C-reactive
protein (Hs-CRP) was measured by using immunity
transmission turbidity in our central laboratory. Medical
histories including hypertension, diabetes, previous heli-
cobactor pylori (HP) infection, intracranial hemorrhage
or gastrointestinal bleeding presumably related to aspirin
use were recorded in case report form. In brief, diagno-
sis of hypertension or diabetes were based on self-
report, treating with anti-hypertensive or anti-diabetic
medications, or measurements of indexes were higher
than normal range as recommended by guideline recom-
mendations [14, 15], respectively. Medicines use such as
aspirin, statins, anti-hypertensive and anti-diabetes drugs
were also recorded in case report form and underwent
re-check by two independent investigators.
Studied endpoints
The efficacy endpoints of present study were to evaluate
whether aspirin could reduce the incidence of CHD in
subjects with documented dyslipidemia; and the safety
endpoints were to assess whether low-dose, enteric-
coated and once-daily aspirin would increase bleeding
risks.
Statistical analysis
Continuous variables are presented with mean ± SD and
categorical variables are presented with the number
(percentages). Statistical significance of differences is an-
alyzed using student t-test or Mann-Whitney U test for
continuous variables and the chi-square or Fisher exact
test for categorical variables. Logistic regression analysis
was applied to calculate odds ratio (OD) and its’ associ-
ated 95 % confidence intervals (CI) of aspirin on inci-
dent CHD and bleeding events. Statistical analysis is
computed using SPSS 18.0 (SPSS Inc, Chicago, IL). All
of the statistical tests were two-sided and considered sta-
tistically significant if P < 0.05.
Results
Clinical characteristics of subjects with and without
aspirin therapy
A total of 202 patients with documented dyslipidemia
were recruited and among them, 138 had been treating
with aspirin before this indexed admission and 64 had
never been treated with aspirin. As shown in Table 1,
male was predominant with more than 50 % of enrolled
subjects, and nearly 50 % of studied subjects in both
groups were smokers. No significant between-group dif-
ferences in blood pressure, heart rate, lipid profiles, FPG,
HbA1c and Hs-CRP were observed. Proportions of sub-
jects with hypertension (26.1 % versus 28.1 %) and
diabetes (13.8 % versus 15.6 %) were also comparable.
Compared to those with aspirin therapy, CHD incidence
was significantly higher in subjects without aspirin
therapy (23.4 % versus 18.1 %, P < 0.05). Based on self-
report, 5 patients in the aspirin group had gastrointes-
tinal bleeding after regularly taking aspirin and no
bleeding event occurred in subjects without aspirin
therapy. Interestingly, patients in the aspirin therapy
group had higher proportion of previous helicobacter
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pylori infection as self-report (8.7 % versus 4.7 %, P <
0.05). No significant between-group differences in med-
ications used were observed.
Clinical characteristics of subjects with and without CHD
All 202 subjects were separated into two groups based
on coronary angiography findings. As shown in Table 2,
compared to subjects without CHD, subjects with CHD
had more male patients, were older and had more
smokers (P < 0.05 for all comparison). And subjects with
CHD had significantly higher heart rate, serum LDL
cholesterol, Lp(a) and Hs-CRP levels. Furthermore,
proportions of subjects with hypertension, diabetes,
gastrointestinal bleeding, HP infection and anti-
hypertensive therapy were also considerably higher in
CHD group compared to without CHD group (P < 0.05
for all comparison).
Logistic regression analysis
Logistic regression analysis was performed to evaluate the
relation between aspirin use and incident CHD and
gastrointestinal bleeding. As shown in Table 3, in CHD
outcome model (efficacy endpoint), after adjusting for
potential confounding covariates including age, gender,
smoking status, SBP, LDL cholesterol, Lp(a), Hs-CRP,
hypertension, diabetes and statins, aspirin therapy reduced
the risk of CHD, with OR of 0.85 (95 % CI: 0.80-0.94,
P < 0.05). In gastrointestinal bleeding outcome model
(safety endpoint), after adjusting for potential confounding






Male (%) 72 (52.3) 33 (51.7)
Age (years) 53.2 ± 8.4 51.7 ± 6.9
Smoking (%) 66 (47.8) 30 (46.9)
SBP (mmHg) 135.7 ± 17.4 131.3 ± 12.8
DBP (mmHg) 71.4 ± 10.3 70.6 ± 11.6
HR (bpm) 75.5 ± 13.2 72.6 ± 13.1
Waist-Hip ratio 0.89 ± 0.03 0.88 ± 0.05
TC (mmol/L) 5.13 ± 0.24 5.11 ± 0.22
TG (mmol/L) 1.54 ± 0.32 1.57 ± 0.30
LDL (mmol/L) 3.36 ± 0.41 3.40 ± 0.36
HDL (mmol/L) 0.93 ± 0.06 0.92 ± 0.06
Lp(a) (mg/L) 238.96 ± 26.45 244.35 ± 33.15
ApoA1 (mmol/L) 1.06 ± 0.33 1.05 ± 0.29
ApoB (mmol/L) 1.10 ± 0.26 1.11 ± 0.30
FPG (mmol/L) 5.3 ± 0.6 5.4 ± 0.5
HbA1c (%) 5.9 ± 0.8 5.8 ± 0.6
Hs-CRP (mg/L) 10.7 ± 3.5 11.4 ± 3.2
Hypertension (%) 36 (26.1) 18 (28.1)
Diabetes (%) 19 (13.8) 10 (15.6)
CHD (%) 25 (18.1)* 15 (23.4)
Intracranial hemorrhage (%) 0 (0) 0 (0)
Gastrointestinal bleeding (%) 5 (3.6)* 0 (0)
HP infection (%) 12 (8.7)* 3 (4.7)
Statins (%) 127 (92.0) 60 (93.8)
Anti-hypertension (%) 27 (19.6) 11 (17.2)
Anti-diabetes (%) 15 (10.9) 8 (12.5)
Denote: * P < 0.05 versus without aspirin group
Table 2 Comparisons between subjects with and without CHD
Variables CHD(n = 40) Without CHD(n = 162)
Male (%) 23(57.5)* 82(50.6)
Age (years) 55.4 ± 8.7* 51.2 ± 7.3
Smoking (%) 22(55.0)* 74(45.7)
SBP (mmHg) 134.2 ± 14.5 132.6 ± 16.3
DBP (mmHg) 73.5 ± 10.1 71.4 ± 8.6
HR (bpm) 77.3 ± 8.0* 71.4 ± 6.6
W-H ratio 0.90 ± 0.04 0.88 ± 0.05
TC (mmol/L) 5.28 ± 0.23 5.04 ± 0.22
TG (mmol/L) 1.66 ± 0.30 1.59 ± 0.37
LDL (mmol/L) 3.49 ± 0.44* 3.20 ± 0.38
HDL (mmol/L) 0.89 ± 0.17 0.92 ± 0.20
Lp(a) (mg/L) 258.56 ± 30.86* 227.16 ± 24.43
ApoA1 (mmol/L) 1.04 ± 0.27 1.07 ± 0.22
ApoB (mmol/L) 1.15 ± 0.33 1.10 ± 0.29
FPG (mmol/L) 5.5 ± 0.5 5.2 ± 0.6
HbA1c (%) 5.9 ± 0.7 5.6 ± 0.5
Hs-CRP (mg/L) 13.4 ± 3.8* 10.7 ± 3.1
Hypertension (%) 16(40.0)* 38(23.5)
Diabetes (%) 9(22.5)* 20(12.3)
Intracranial hemorrhage (%) 0(0) 0(0)
Gastrointestinal bleeding (%) 3(7.5)* 2(1.2)
HP infection (%) 4(10.0)* 11(6.8)
Statins (%) 37(92.5) 150(92.6)
Anti-hypertension (%) 11(27.5)* 27(16.7)
Anti-diabetes (%) 5(12.5) 18(11.1)
Denote: * P < 0.05 versus without CHD group
Table 3 Odds ratio of CHD and gastrointestinal bleeding in
subjects with aspirin
Outcomes With Aspirin (n = 138) OR (95 % CI)
CHD, n (%) 25 (18.1) 0.85 (0.80–0.94)*
Gastrointestinal bleeding, n (%) 5 (3.6) 1.16 (0.99–1.52)
Denote: *P < 0.05
In CHD outcome model, fully adjusting for age, gender, smoking, SBP, LDL
cholesterol, Lp(a), Hs-CRP, hypertension, diabetes and statins
In Gastrointestinal bleeding model, fully adjusting for age, gender, smoking,
LDL cholesterol, hypertension, diabetes and HP infection
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covariates including age, gender, smoking, LDL choles-
terol, hypertension and diabetes, the risk of gastrointes-
tinal bleeding associated with aspirin therapy remained
significant (OR: 1.88 and 95 % CI: 1.56-2.33, P < 0.05).
Discussion
Our preliminary data show that aspirin may be beneficial
for decreasing incidence of CHD as documented by cor-
onary angiography in subjects with dyslipidemia. None-
theless, aspirin may also slightly increase gastrointestinal
bleeding risk, especially in subjects with previous HP in-
fection which deserves further investigation.
Aspirin now has been broadly used for ASCVD sec-
ondary prevention owing to its compelling evidence on
improving cardiovascular outcomes [16]. Nonetheless,
data from primary prevention studies are controversial.
In addition, aspirin therapy may increase bleeding risk
and the major mechanisms are twofold [8]. On the one
hand, aspirin has effect on inhibiting cyclooxygenase
thereby reducing platelet activation and adhesion. On
the other hand, aspirin also has unwanted effect with re-
spect to causing gastritis or gastric ulceration. Therefore,
it should be cautious to balance the risk and benefit of
prescribing aspirin before more solid evidence is avail-
able to demonstrate aspirin should be applied to subjects
with ASCVD risk factors such as dyslipidemia.
We performed a cross-sectional research to investigate
the relation between aspirin use and incidence of CHD
as diagnosed by indexed coronary angiography. All our
recruited subjects were diagnosed with dyslipidemia and
more than 90 % was treated with statins. Results showed
that after fully adjusting for potential confounding co-
variates, aspirin therapy was beneficial for reducing the
incidence of CHD. However, the data from the Japanese
Primary Prevention Project (JPPP) trial showed that as-
pirin therapy was not beneficial for reducing composite
cardiovascular outcomes including nonfatal ischemic
stroke, myocardial infarction and vascular death [3].
There were several differences between our present
study and the JPPP trial. First of all, the differences in
studied design and ethnic group might largely account
for these discrepancies. Second, we only investigated the
effect of aspirin on CHD incidence while the JPPP trial
additionally included ischemic stroke and vascular death
as efficacy endpoints. It might be possible that aspirin
has different effects on coronary artery and cerebral ves-
sels, given the heterogeneity of mechanisms underlying
cerebrovascular ischemia [17]. Third, subjects in our
present study were much younger than those in the JPPP
trial, and aging might offset the potential benefits of as-
pirin therapy [18]. Moreover, only a minority of subjects
in our present study had co-morbidities such as hyper-
tension and diabetes, which indicated that subjects in
our present study were at relatively lower ASCVD risk
compared to those in the JPPP trial. Furthermore, in an-
other study investigating the effect of low-dose aspirin
to prevent cardiovascular events in subjects with type 2
diabetes mellitus, Hisao and colleagues reported that on
cardiovascular benefits were found [5]. In a large meta-
analysis, it was also revealed that aspirin for primary
prevention, the cardiovascular benefit is uncertain. How-
ever, it might increase bleeding risk [1]. Likewise, differ-
ent study design and populations should largely be
accounted for these discrepancies. In addition, with re-
spect to our present findings, we considered that the
benefit of aspirin for ASCVD primary prevention might
be possible for a specific population but not the whole
general population.
We further evaluated the incidence of bleeding events
presumably associated with aspirin therapy. We mainly
included intracranial hemorrhage and gastrointestinal
bleeding as safety endpoints because these two adverse
events were accounted for a vast majority of aspirin-
related bleeding complications. Based on self-report, 5
cases of gastrointestinal bleeding presumably associated
with aspirin therapy were identified and after initially
adjusting for potential confounding factors, aspirin ther-
apy appeared to increase gastrointestinal bleeding risk.
Nonetheless, bleeding risk associated with aspirin ther-
apy was attenuated to nonsignificant after additionally
adjusting for HP infection. As is well known that HP in-
fection increases the incidence of gastric and duodenal
ulceration [19, 20], and the prevalence of HP infection
in China is much higher than the other developed coun-
tries [21]. Therefore, it was conceivable that subjects
with HP infection in our current study might have oc-
cult gastrointestinal ulceration which exposed them at
higher risk of gastrointestinal bleeding. These findings
indicated that screening for HP infection might help re-
duce potential bleeding risk associated with aspirin ther-
apy. In addition, smoking may also increase bleeding
risk in relation to its effects on impairing coagulatory
system although since no significant between-group dif-
ference in smoking rate was observed.
Comparisons between subjects with and without CHD
revealed that subjects with CHD might at increased risk
of gastrointestinal bleeding. For example, subjects with
CHD were with male predominant, older, higher per-
centages of smoking, diabetes and HP infection, all of
which were significant contributors of gastrointestinal
bleeding. These findings might indicate that subjects at
increased risk of CHD might also have a higher risk of
gastrointestinal bleeding concomitantly.
There were several limitations of our current study. First
of all, this was a cross-sectional research and the results
from present study could not be used to conclude a causal
relationship. Rather, present study might provide pilot
data for future randomized perspective study to explore
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the effect of aspirin for CHD primary prevention. Second,
we did not include ischemic stroke as an efficacy outcome
because we did not have solid evidence to diagnose ische-
mic stroke in the absence of compute tomography scan.
Owing to a high prevalence and incidence of ischemic
stroke in Chinese population, it is clinically relevant to
include ischemic stroke as an efficacy endpoint in future
study. Third, the diagnoses of gastrointestinal bleeding and
HP infection were based on self-report and therefore, the
accuracy of the safety endpoint evaluation might be some-
what compromised. However, we had enquired both the
patients’ immediate relative and charged physicians in other
hospitals. Therefore, we considered that the possibility of
diagnostic inaccuracy was small. Last but not the least, a
small sample size of present study was not adequately
powered to detect potential between-group differences.
Conclusion
Our current study shows that in subjects with dyslipidemia,
low-dose, enteric-coated, once-daily aspirin is beneficial for
reducing the incidence of CHD while only slightly increase
gastrointestinal bleeding risk.
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